Evidence map›Paper›PMID 26372797›Full record

ReviewExpert opinion on biological therapy2015

Update on reslizumab for eosinophilic asthma.

Juan Carlos Cardet, Elliot Israel

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert opinion on biological therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Role of biologics in severe eosinophilic asthma - focus on reslizumab.Therapeutics and clinical risk management · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Juan Carlos Cardeta 1 Harvard Medical School , Boston, MA, USA.
Elliot Israeld 4 Harvard Medical School. Director of Clinical Research, Division of Pulmonary Medicine, Brigham and Women's Hospital , 75 Francis st, Boston, MA 02115, USA +1 61 77 32 81 10 ; +1 61 77 32 74 21 ; eisrael@partners.org.
Brigham and Women's Hospital · US

Funding

HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
Therapeutic Control of Aspirin-Exacerbated Respiratory DiseaseU19AI095219 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Joshua A Boyce · 2011 to 2026
$29.1M
NCRR NIH HHS UL1 RR025758NIAID NIH HHS U19 AI095219NIAID NIH HHS U19AI095219).
6 · The paper itself

Abstract

introductionPatients with severe eosinophilic asthma have an unmet need for novel and efficacious treatments. Reslizumab is one of the three monoclonal antibodies targeting the IL-5 pathway and has been found in Phase IIIb clinical trials to reduce asthma exacerbations, control asthma-related symptoms and improve pulmonary function in patients with eosinophilic asthma. AREAS COVERED: In this article, we discuss the results of asthma clinical trials using reslizumab, beginning with a discussion of the relationship between eosinophils, IL-5 and asthma. We conducted PubMed searches using the terms 'reslizumab', 'anti-IL-5', 'eosinophilic asthma', 'IL-5 asthma'. We also searched ClinicalTrials.gov for 'reslizumab', 'reslizumab asthma', 'SCH 55700', 'SCH 55700 asthma', 'Cinquil' and 'Cinquil asthma'. EXPERT OPINION: Reslizumab and other anti-IL-5 therapies have seen success in recent trials through more stringent study participant selection targeting eosinophilic inflammation. This selection can now be based on simple blood counts. These drugs have shown a very good safety profile, but long-term safety data are not yet available. Approval for these drugs is eagerly awaited by clinicians and patients alike.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAsthmaClinical Trials as TopicDatabases, FactualEosinophilsHumansInterleukin-5Signal TransductionAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedInterleukin-5reslizumabanti-IL-5 therapyasthmaeosinophileosinophilic inflammationIL-5monoclonal antibodyreslizumab

Identifiers

PMID26372797
PMCPMC5161345
OpenAlexW1786965289

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.